Jan 04 2022: Dipyanone confirmed. Sample was re-analyzed alongside re-engineered reference standard. GC/MS chromatogram for correct standard added below, left.
Sep 10 2021: We now believe this sample, originally considered unidentified by our lab, is Dipyanone. The reference standard for Dipyanone that was sent to our lab (pictured below, left) from Cayman in August was not correct. This is a very rare event.
This sample will be re-analyzed when the corrected standard for Dipyanone reaches the lab, expected by mid-October 2021.
Sep 4 2021: We purchased a reference standard for Dipyanone, but the MS didn't match. However we are now looking into whether it's possible the standard we received might be the wrong chemical.
Aug 4 2021: A Dipyanone standard was sourced and purchased, and this sample was re-analyzed. Sample is not Dipyanone. It remains unidentified for now.
Jun 8 2021: The mass spectrum for Dipipanone and the spectrum for the drug in this sample (pictured, left) are very similar, but not identical. (The Dipipanone one is also shown for comparison, bottom left.) Very little information and no certified standard available for Dipyanone, as of June 7, 2021.
The submitter says the sample was sold as 'Dipyanone', which we believe is the pyrrolidine analog of Dipipanone. Our analysis shows that this sample is not Dipipanone, but it could possibly be Dipyanone.
DrugsData tests all psychoactive drugs including ecstasy tablets, powders, research chemicals, novel pschoactive substances, and other drugs through our DEA-licensed laboratory. Ecstasy/Molly tablets cost $100. Recreational drug powder/crystal/blotter costs $100. Pharmaceuticals, supplements and all others cost $150 per analysis.
Should the public have access to independent analysis of the products they consume?
The vast majority of analyses of over-the-counter, prescription, and recreational drugs are performed in secret with no independent oversite or review. No other historical record, free from politically-controlled agencies, is currently available in North America nor most other parts of the world.
DrugsData, a project of Erowid Center, needs the support of professionals, students, parents, individuals with means, and small foundations for a total yearly budget of around $120,000 USD. Erowid Center's general budget and the co-pays we require fund most of this cost.
not DipyanoneSep 10 2021: We now believe this sample, originally considered unidentified by our lab, is Dipyanone. The reference standard for Dipyanone that was sent to our lab (pictured below, left) from Cayman in August was not correct. This is a very rare event.
This sample will be re-analyzed when the corrected standard for Dipyanone reaches the lab, expected by mid-October 2021.
Aug 4 2021: A Dipyanone standard was sourced and purchased, and this sample was re-analyzed.
Sample is not Dipyanone. It remains unidentified for now.Jun 8 2021: The mass spectrum for Dipipanone and the spectrum for the drug in this sample (pictured, left) are very similar, but not identical. (The Dipipanone one is also shown for comparison, bottom left.) Very little information and no certified standard available for Dipyanone, as of June 7, 2021.
The submitter says the sample was sold as 'Dipyanone', which we believe is the pyrrolidine analog of Dipipanone. Our analysis shows that this sample is not Dipipanone, but it could possibly be Dipyanone.